keyword
MENU ▼
Read by QxMD icon Read
search

2015 monoclonal antibodies

keyword
https://www.readbyqxmd.com/read/29774158/efficacy-of-vedolizumab-for-induction-of-clinical-response-and-remission-in-patients-with-moderate-to-severe-inflammatory-bowel-disease-who-failed-at-least-two-tnf-antagonists
#1
Martine De Vos, Barbara Dhooghe, Severine Vermeire, Edouard Louis, Fazia Mana, Ann Elewaut, Peter Bossuyt, Filip Baert, Catherine Reenaers, Marc Van Gossum, Elisabeth Macken, Marc Ferrante, Pieter Hindryckx, Olivier Dewit, Tom Holvoet, Denis Franchimont
Background: Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). Objective: The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life. Methods: A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015)...
April 2018: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/29773326/tremelimumab-combined-with-durvalumab-in-patients-with-mesothelioma-nibit-meso-1-an-open-label-non-randomised-phase-2-study
#2
Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte, Anna Maria Di Giacomo, Michele Maio
BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first-line or second-line chemotherapy compared with placebo in the DETERMINE study. We aimed to investigate the efficacy and safety of first-line or second-line tremelimumab combined with durvalumab, an anti-PD-L1 monoclonal antibody, in patients with malignant mesothelioma. METHODS: In this open-label, non-randomised, phase 2 trial, patients with unresectable pleural or peritoneal mesothelioma received intravenous tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses...
May 14, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29770231/cardiovascular-outcomes-of-pcsk9-inhibitors-with-special-emphasis-on-its-effect-beyond-ldl-cholesterol-lowering
#3
REVIEW
Dhrubajyoti Bandyopadhyay, Kumar Ashish, Adrija Hajra, Arshna Qureshi, Raktim K Ghosh
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-C) metabolism. PCSK9 inhibitors are monoclonal antibodies that target PCSK9 protein in liver and inhibiting this protein leads to drastically lowering harmful LDL-C level in the bloodstream. Despite widespread use of the statin, not all the high-risk patients were able to achieve targeted level of LDL-C...
2018: Journal of Lipids
https://www.readbyqxmd.com/read/29750753/immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-alone-versus-immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-in-combination-with-anti-rankl-denosumuab-in-malignant-melanoma-a-retrospective-analysis-at-a-tertiary-care-center
#4
Muhammad Z Afzal, Keisuke Shirai
Denosumab is a monoclonal antibody against RANK ligand with a role in the prevention of skeletal-related events and is also known to possess antitumor properties. In this retrospective review, we aim to evaluate the synergist effect of a combination therapy with immune checkpoint inhibitors and denosumab in malignant melanoma patients. Patients of 18 years of age or older with a diagnosis of malignant melanoma who have received immune checkpoint inhibitors and denosumab between June 2015 and May 2017 were divided into two cohorts: cohort A (immune checkpoint inhibitors only) and cohort B (immune checkpoint inhibitors and denosumab)...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29748955/investigational-agents-in-immunotherapy-a-new-horizon-for-the-treatment-of-multiple-myeloma
#5
REVIEW
Cindy Varga, Jacob P Laubach, Kenneth C Anderson, Paul G Richardson
The treatment of multiple myeloma (MM) has gone through several major advances over the last 5 years with the introduction of next generation proteasome inhibitors (PI; carfilzomib, ixazomib) and immunomodulatory derivatives (IMiD; pomalidomide), with these new agents having a substantial impact on patient outcome. However, despite these advances, MM remains a highly resistant disease given its propensity for clonal heterogeneity and its complex interaction with the surrounding bone marrow microenvironment...
May 10, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29740494/addition-of-bevacizumab-to-systemic-therapy-for-locally-advanced-and-metastatic-nasopharyngeal-carcinoma
#6
Hui-Jie Zhang, Gao-Le Yuan, Qi-Lian Liang, Xiao-Xia Peng, Shao-Ang Cheng, Liang Jiang
Radiotherapy is a vital treatment option for patients with nasopharyngeal carcinoma (NPC). Concurrent cisplatin-based radiochemotherapy with or without adjuvant chemotherapy had acquired good clinical effects with good local control rates. However, a number of patients present with metastasis following systemic regimens or initial diagnosis of locally advanced NPC, which cause difficulty for subsequent therapy. Therefore, there is an urgent requirement to discover novel targeted therapies. The present report describes one case of a patient with NPC and multiple metastases...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29706812/usefulness-of-alirocumab-and-evolocumab-for-the-treatment-of-patients-with-diabetic-dyslipidemia
#7
REVIEW
Jun Zhang, Kristen M Tecson, Natalia A Rocha, Peter A McCullough
In 2015, the US Food and Drug Administration (FDA) approved the anti-proprotein convertase subtilsin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, to treat patients with hypercholesterolemia and mixed dyslipidemia. Since then, considerable attention has been paid to the use of these monoclonal antibodies for the treatment of diabetic dyslipidemia with a goal of reducing the risk for cardiovascular disease. Recently, consensus statements on the clinical use of PCSK9 inhibitors in patients with type 2 diabetes mellitus, who are unable to achieve the goal of low-density lipoprotein cholesterol (<70 mg/dL or <1...
April 2018: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/29685815/safety-and-efficacy-of-eculizumab-in-guillain-barr%C3%A3-syndrome-a-multicentre-double-blind-randomised-phase-2-trial
#8
Sonoko Misawa, Satoshi Kuwabara, Yasunori Sato, Nobuko Yamaguchi, Kengo Nagashima, Kanako Katayama, Yukari Sekiguchi, Yuta Iwai, Hiroshi Amino, Tomoki Suichi, Takanori Yokota, Yoichiro Nishida, Tadashi Kanouchi, Nobuo Kohara, Michi Kawamoto, Junko Ishii, Motoi Kuwahara, Hidekazu Suzuki, Koichi Hirata, Norito Kokubun, Ray Masuda, Juntaro Kaneko, Ichiro Yabe, Hidenao Sasaki, Ken-Ichi Kaida, Hiroshi Takazaki, Norihiro Suzuki, Shigeaki Suzuki, Hiroyuki Nodera, Naoko Matsui, Shoji Tsuji, Haruki Koike, Ryo Yamasaki, Susumu Kusunoki
BACKGROUND: Despite the introduction of plasmapheresis and immunoglobulin therapy, many patients with Guillain-Barré syndrome still have an incomplete recovery. Evidence from pathogenesis studies suggests the involvement of complement-mediated peripheral nerve damage. We aimed to investigate the safety and efficacy of eculizumab, a humanised monoclonal antibody against the complement protein C5, in patients with severe Guillain-Barré syndrome. METHODS: This study was a 24 week, multicentre, double-blind, placebo-controlled, randomised phase 2 trial done at 13 hospitals in Japan...
April 20, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29669959/evaluation-of-the-fusion-partner-cell-line-spymeg-for-obtaining-human-monoclonal-antibodies-against-influenza-b-virus
#9
Priyanka Soni, Atsuhiro Yasuhara, Toru Takenaga, Kiyoko Iwatsuki-Horimoto, Ryuta Uraki, Mutsumi Ito, Tadahiro Sasaki, Kazuyoshi Ikuta, Seiya Yamayoshi, Yoshihiro Kawaoka
Influenza B virus has been known to infect humans and other animals, including seals. Vaccination efficacy varies across seasons. Human monoclonal antibodies (mAbs) can be useful for developing novel vaccines, guided by epitope analysis, and can be used therapeutically. Hybridoma technology has been used to make mAbs. Here we evaluated SPYMEG as a fusion partner cell line for human mAb generation specific to influenza B hemagglutinin (HA). SPYMEG is a human/murine myeloma partner cell line that has previously been used to generate human mAbs that recognize the HA of influenza A and B viruses...
April 17, 2018: Journal of Veterinary Medical Science
https://www.readbyqxmd.com/read/29618399/the-validation-of-the-rida-%C3%A2-quick-gliadin-for-aoac-research-institute
#10
Markus Lacorn, Thomas Weiss, Nicole Klass, Patrick Bird, M Joseph Benzinger, James Agin, David Goins
RIDA® QUICK Gliadin is an immuno-chromatographic test for the detection of gluten in foods, on surfaces, and in Cleaning-in-Place (CIP) waters. This test kit has been adopted as Final Action AOAC INTERNATIONAL Official Methods of Analysis SM 2015.16 for gluten in corn products. The assay is based on the monoclonal antibody R5, which recognizes gluten in wheat, barley, and rye. Four different surfaces were contaminated with a gliadin material and analyzed by a direct swabbing of the surface with the dip-stick...
April 4, 2018: Journal of AOAC International
https://www.readbyqxmd.com/read/29611659/comparison-of-serum-concentrations-of-environmental-allergen-specific-ige-in-atopic-and-healthy-nonatopic-horses
#11
P Wilkołek, W Sitkowski, M Szczepanik, Ł Adamek, M Pluta, I Taszkun, M Gołyński, A Malinowska
Allergic responses in humans, horses and other species are mediated by immunoglobulin E (IgE) antibodies. Serum testing to detect allergen-specific IgE antibodies has been developed for dogs, cats and horses; this allows for the identification of allergens and determination of appropriate allergen- specific immunotherapies. This study compared serum allergen-specific IgE concentrations in atopic and healthy horses. The study was performed on Malopolski breed atopic (n=21) and nonatopic (n=21) clinically healthy horses...
December 2017: Polish Journal of Veterinary Sciences
https://www.readbyqxmd.com/read/29603214/tumor-necrosis-factor-alpha-inhibitors-and-risk-of-non-hodgkin-lymphoma-in-a-cohort-of-adults-with-rheumatologic-conditions
#12
Gregory S Calip, Pritesh R Patel, Sruthi Adimadhyam, Shan Xing, Zhaoju Wu, Karen Sweiss, Glen T Schumock, Todd A Lee, Brian C-H Chiu
Based on limited evidence, the U.S. Food and Drug Administration (FDA) issued a black box warning for the use of tumor necrosis factor-alpha inhibitors (TNFIs) and risk of non-Hodgkin lymphoma (NHL). Our objective was to determine the risk of NHL associated with TNFI use by duration and type of anti-TNF agent. We performed a nested case-control study within a retrospective cohort of adults with rheumatologic conditions from a U.S. commercial health insurance database between 2009 and 2015. Use of TNFIs (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol) and conventional-synthetic disease-modifying antirheumatic drugs (csDMARDs) was identified, and conditional logistic regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) for risk of NHL...
March 30, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29560093/capillary-density-has-no-value-as-an-early-biomarker-of-bevacizumab-efficacy-in-metastatic-colorectal-cancers-a-prospective-clinical-trial
#13
Jean-David Fumet, Aurélie Bertaut, Leila Bengrine, Patricia Lapierre, Julie Vincent, François Ghiringhelli, Nicolas Falvo
Background: Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density. We evaluated the link between decreased capillary density and the response to bevacizumab-based chemotherapy. Results: Overall, 43 patients with metastatic colorectal cancer treated with first-line bevacizumab-based chemotherapy were enrolled...
February 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29559561/safety-and-antitumor-activity-of-pembrolizumab-in-patients-with-estrogen-receptor%C3%A2-positive-human-epidermal-growth-factor-receptor-2%C3%A2-negative-advanced-breast-cancer
#14
Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A Ott, Sarina A Piha-Paul, Phillipe L Bedard, Jasgit Sachev, Christophe Le Tourneau, Emilie M J van Brummelen, Andreea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R Tan
PURPOSE: We investigated the safety and antitumor activity of the anti-programmed death 1 monoclonal antibody pembrolizumab in patients with estrogen receptor‒positive (ER+)/human epidermal growth factor receptor 2-negative (HER2- ) advanced breast cancer with programmed death ligand 1‒positive (PD-L1‒positive) tumors in the phase Ib open-label, multicohort KEYNOTE-028 (NCT02054806) study. EXPERIMENTAL DESIGN: Patients with ER+/HER2- advanced breast cancer with PD-L1‒positive tumors (combined positive score ≥1) received pembrolizumab (10 mg/kg every 2 weeks) up to 2 years or until confirmed progression/intolerable toxicity...
March 20, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29545284/omalizumab-effectiveness-in-patients-with-severe-allergic-asthma-according-to-blood-eosinophil-count-the-stellair-study
#15
Marc Humbert, Camille Taillé, Laurence Mala, Vincent Le Gros, Jocelyne Just, Mathieu Molimard
Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate and a combination of both...
May 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29544133/no-prognostic-significance-of-immunophenotypic-changes-at-the-end-of-remission-induction-therapy-in-children-with-b-lineage-acute-lymphoblastic-leukemia
#16
Qingkai Dai, Xiaojuan Liu, Hui Yang, Siqi Guo, Yuefang Wang, Luyun Peng, Lei Ye, Lan Chen, Chunqi Lai, Qi Chen, Ge Zhang, Yongmei Jiang
Detection of aberrant antigen expression in acute lymphoblastic leukemia (ALL) by flow cytometric is proposed for the quantification of minimal residual disease (MRD). There are few studies that investigate the stability of the antigen expression in children with B lineage ALL at the end of remission induction therapy and determine its prognostic impact. Between 2010 and 2015, 691 bone marrow specimens of childhood ALL were sent at diagnosis for immunophenotypic characterization, and follow-up samples for MRD were analyzed on day 33...
May 2018: Leukemia Research
https://www.readbyqxmd.com/read/29536254/-end-of-life-therapy-for-patients-dying-with-cancer-a-retrospective-database-study
#17
Fabiola Fuchs, Martin Robausch
BACKGROUND: The topic of "medical oversupply at the end-of-life" is being discussed intensively internationally. The aim of this paper is to present the data of end-of-life care in one region in Austria (Lower Austria). METHODS: The data basis for the end-of-life indicators was the routine data (secondary data analysis) of the Lower Austrian District Health Insurance Fund (NÖGKK) from 2015. The basic population consisted of persons with inpatient hospitalization with a cancer diagnosis...
March 13, 2018: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29530667/preliminary-results-for-avelumab-plus-axitinib-as-first-line-therapy-in-patients-with-advanced-clear-cell-renal-cell-carcinoma-javelin-renal-100-an-open-label-dose-finding-and-dose-expansion-phase-1b-trial
#18
Toni K Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David McDermott, Paul B Robbins, David D Chism, Daniel Cho, Michael B Atkins, Michael S Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Camilla Fowst, Alessandra di Pietro, Brian I Rini
BACKGROUND: The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with their use alone. Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma...
April 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29523646/phase-ii-study-of-preoperative-treatment-with-external-radiotherapy-plus-panitumumab-in-low-risk-locally-advanced-rectal-cancer-rap-study-star-03
#19
Carmine Pinto, Maurizio Di Bisceglie, Francesca Di Fabio, Annamaria Bochicchio, Tiziana Latiano, Stefano Cordio, Gerardo Rosati, Carlo Aschele, Antonella Marino, Francesca Bergamo, Sara Bustreo, Luca Frassineti, Fortunato Ciardiello, Angela Damato, Stefania Giaquinta, Daniela Baldari, Luca Boni
BACKGROUND: Treatment with fluoropyrimidines and concomitant long-course external radiotherapy (RTE) is the standard of care in locally advanced rectal cancer (LARC) preoperative chemoradiation. A randomized phase II study (RaP/STAR-03) was conducted that aimed to evaluate the activity and safety of the monoclonal antibody anti-epidermal growth factor receptor panitumumab as a single agent in combination with radiotherapy in low-risk LARC preoperative treatment. MATERIALS AND METHODS: Patients had adenocarcinoma of the mid-low rectum, cT3N- or cT2-T3N+, KRAS wild-type status, and negative circumferential radial margin...
March 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29517449/melanoma-in-golden-and-king-wildebeests-connochaetes-taurinus
#20
Shakirat A Adetunji, Rosina C Krecek, Nicolize O'Dell, Leon Prozesky, Johan Steyl, Angela M Arenas-Gamboa
Pigmentation of the skin is a crucial component in the pathogenesis of melanocytic neoplasms and other skin-related tumors, as melanin is known to function in both the absorbance of ultraviolet radiation and as an antioxidant. Very limited information exists regarding the incidence and metastatic potential of neoplastic conditions of the skin in game animals, especially wildebeests, relative to domestic animals. Four cases of cutaneous melanoma in color-variant golden and king wildebeests ( Connochaetes taurinus) (from 2014 to 2015) in South Africa were investigated...
March 2018: Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians
keyword
keyword
65728
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"